Charles River Laboratories Comprehensive Income 2010-2024 | CRL
Charles River Laboratories comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Charles River Laboratories comprehensive income for the quarter ending June 30, 2024 was $-0.270B, a 29.5% increase year-over-year.
- Charles River Laboratories comprehensive income for 2023 was $-0.196B, a 25.04% decline from 2022.
- Charles River Laboratories comprehensive income for 2022 was $-0.262B, a 59.07% increase from 2021.
- Charles River Laboratories comprehensive income for 2021 was $-0.165B, a 18.63% increase from 2020.
| Charles River Laboratories Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2023 | $-196 |
| 2022 | $-262 |
| 2021 | $-165 |
| 2020 | $-139 |
| 2019 | $-178 |
| 2018 | $-173 |
| 2017 | $-145 |
| 2016 | $-254 |
| 2015 | $-136 |
| 2014 | $-74 |
| 2013 | $5 |
| 2012 | $7 |
| 2011 | $5 |
| 2010 | $34 |
| 2009 | $45 |
| Charles River Laboratories Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-06-30 | $-270 |
| 2024-03-31 | $-250 |
| 2023-12-31 | $-196 |
| 2023-09-30 | $-268 |
| 2023-06-30 | $-208 |
| 2023-03-31 | $-239 |
| 2022-12-31 | $-262 |
| 2022-09-30 | $-396 |
| 2022-06-30 | $-259 |
| 2022-03-31 | $-175 |
| 2021-12-31 | $-165 |
| 2021-09-30 | $-133 |
| 2021-06-30 | $-108 |
| 2021-03-31 | $-127 |
| 2020-12-31 | $-139 |
| 2020-09-30 | $-195 |
| 2020-06-30 | $-213 |
| 2020-03-31 | $-219 |
| 2019-12-31 | $-178 |
| 2019-09-30 | $-178 |
| 2019-06-30 | $-166 |
| 2019-03-31 | $-163 |
| 2018-12-31 | $-173 |
| 2018-09-30 | $-159 |
| 2018-06-30 | $-154 |
| 2018-03-31 | $-124 |
| 2017-12-31 | $-145 |
| 2017-09-30 | $-183 |
| 2017-06-30 | $-208 |
| 2017-03-31 | $-242 |
| 2016-12-31 | $-254 |
| 2016-09-30 | $-166 |
| 2016-06-30 | $-150 |
| 2016-03-31 | $-143 |
| 2015-12-31 | $-136 |
| 2015-09-30 | $-121 |
| 2015-06-30 | $-90 |
| 2015-03-31 | $-109 |
| 2014-12-31 | $-74 |
| 2014-09-30 | $-18 |
| 2014-06-30 | $14 |
| 2014-03-31 | $1 |
| 2013-12-31 | $5 |
| 2013-09-30 | $-2 |
| 2013-06-30 | $-19 |
| 2013-03-31 | $-14 |
| 2012-12-31 | $7 |
| 2012-09-30 | $16 |
| 2012-06-30 | $2 |
| 2012-03-31 | $13 |
| 2011-12-31 | $5 |
| 2011-09-30 | $26 |
| 2011-06-30 | $39 |
| 2011-03-31 | $42 |
| 2010-12-31 | $34 |
| 2010-09-30 | $36 |
| 2010-06-30 | $20 |
| 2010-03-31 | $33 |
| 2009-12-31 | $45 |
| 2009-09-30 | $44 |
| 2009-06-30 | $20 |
| 2009-03-31 | $-19 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.285B | $4.129B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $98.658B | 12.24 |
| Cencora (COR) | United States | $49.082B | 18.10 |
| DiDi Global (DIDIY) | China | $23.427B | 0.00 |
| ICON (ICLR) | Ireland | $17.504B | 15.59 |
| Natera (NTRA) | United States | $16.570B | 0.00 |
| Viatris (VTRS) | United States | $15.624B | 4.81 |
| Avantor (AVTR) | United States | $15.178B | 22.75 |
| Revvity (RVTY) | United States | $14.682B | 25.50 |
| BioMerieux (BMXMF) | France | $13.087B | 0.00 |
| CochLear (CHEOY) | Australia | $12.998B | 0.00 |
| Solventum (SOLV) | United States | $12.357B | 0.00 |
| Doximity (DOCS) | United States | $11.372B | 67.31 |
| Medpace Holdings (MEDP) | United States | $11.301B | 31.84 |
| HealthEquity (HQY) | United States | $8.756B | 47.52 |
| Sonic Healthcare (SKHHY) | Australia | $8.590B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $7.202B | 33.53 |
| Life Times (LTH) | United States | $5.139B | 34.01 |
| Sotera Health (SHC) | United States | $4.509B | 24.12 |
| Organon (OGN) | United States | $4.144B | 4.18 |
| Surgery Partners (SGRY) | United States | $3.996B | 44.27 |
| BrightSpring Health Services (BTSG) | United States | $3.489B | 74.22 |
| PACS (PACS) | United States | $3.347B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.580B | 0.00 |
| Concentras Parent (CON) | United States | $2.505B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.471B | 0.00 |
| Premier (PINC) | United States | $2.314B | 11.55 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.016B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.856B | 48.90 |
| Teladoc Health (TDOC) | United States | $1.689B | 0.00 |
| Progyny (PGNY) | United States | $1.540B | 27.08 |
| Pediatrix Medical (MD) | United States | $1.371B | 13.41 |
| Establishment Labs Holdings (ESTA) | $1.266B | 0.00 | |
| CareDx (CDNA) | United States | $1.252B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.058B | 7.16 |
| Embecta (EMBC) | United States | $0.910B | 6.07 |
| Agilon Health (AGL) | United States | $0.890B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.809B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| SBC Medicals (SBC) | United States | $0.723B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.516B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.459B | 0.00 |
| DocGo (DCGO) | United States | $0.411B | 15.46 |
| Enhabit (EHAB) | United States | $0.403B | 34.83 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.363B | 0.00 |
| LifeMD (LFMD) | United States | $0.308B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.248B | 0.00 |
| ModivCare (MODV) | United States | $0.231B | 12.54 |
| Beauty Health (SKIN) | United States | $0.218B | 0.00 |
| Biodesix (BDSX) | United States | $0.205B | 0.00 |
| Nutex Health (NUTX) | United States | $0.152B | 0.00 |
| MultiPlan (MPLN) | United States | $0.137B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.107B | 0.00 |
| So-Young (SY) | China | $0.088B | 21.28 |
| Singular Genomics Systems (OMIC) | United States | $0.057B | 0.00 |
| Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.054B | 0.00 |
| OncoCyte (OCX) | United States | $0.049B | 0.00 |
| NeueHealth (NEUE) | United States | $0.042B | 1.10 |
| Co-Diagnostics (CODX) | United States | $0.038B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.028B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.028B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| Oncology Institute (TOI) | United States | $0.020B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |